Emma Zattarin

981 total citations
41 papers, 500 citations indexed

About

Emma Zattarin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Emma Zattarin has authored 41 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Emma Zattarin's work include Cancer Immunotherapy and Biomarkers (10 papers), Advanced Breast Cancer Therapies (9 papers) and Breast Cancer Treatment Studies (6 papers). Emma Zattarin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Advanced Breast Cancer Therapies (9 papers) and Breast Cancer Treatment Studies (6 papers). Emma Zattarin collaborates with scholars based in Italy, United States and United Kingdom. Emma Zattarin's co-authors include Filippo de Braud, Francesca Ligorio, Claudio Vernieri, Riccardo Lobefaro, Rita Leporati, Giuseppe Capri, Giulia Bianchi, Giuseppe Procopio, Elena Verzoni and Marco Stellato and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Emma Zattarin

39 papers receiving 494 citations

Peers

Countries citing papers authored by Emma Zattarin

Since Specialization

Citations

This map shows the geographic impact of Emma Zattarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Zattarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Zattarin more than expected).

Fields of papers citing papers by Emma Zattarin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Zattarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Zattarin. The network helps show where Emma Zattarin may publish in the future.

Co-authorship network of co-authors of Emma Zattarin

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Zattarin. A scholar is included among the top collaborators of Emma Zattarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Zattarin. Emma Zattarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results	The Breast	Alice Bernasconi, Emma Zattarin et al.	1
2	“Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”	The Breast	Laura Pala, Eleonora Pagan et al.	1
3	Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis	EClinicalMedicine	Laura Pala, Eleonora Pagan et al.	5
4	Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials	The Breast	Laura Pala, Tommaso De Pas et al.	1
5	Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research	Clinical Cancer Research	Fabio Conforti, Laura Pala et al.	1
6	Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review	Current Oncology	Tommaso De Pas, Giovanna Rossi et al.	4
7	Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis	Seminars in Oncology	Laura Pala, Tommaso De Pas et al.	1
8	Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities	Critical Reviews in Oncology/Hematology	Emma Zattarin, Riccardo Lobefaro et al.	2
9	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy	Future Oncology	Emma Zattarin, Sara Manglaviti et al.	3
10	Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison	Clinical Breast Cancer	Riccardo Lobefaro, Luigi Mariani et al.	4
11	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer	Cancer Letters	Francesca Ligorio, Lorenzo Castagnoli et al.	31
12	Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors	Journal of Personalized Medicine	Mario Occhipinti, Marta Brambilla et al.	8
13	300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study	Annals of Oncology	Emma Zattarin, Chiara Fabbroni et al.	2
14	175P Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)–positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy	Annals of Oncology	Francesca Ligorio, Lorenzo Castagnoli et al.	1
15	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes	Cancer Treatment Reviews	Mélanie Claps, Alessia Mennitto et al.	42
16	Current Understanding of Urachal Adenocarcinoma and Management Strategy	Current Oncology Reports	Mélanie Claps, Marco Stellato et al.	27
17	146P Safety and metabolic effects of fasting-mimicking diet in breast cancer patients	Annals of Oncology	Claudio Vernieri, Alessandra Raimondi et al.	1
18	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer	Frontiers in Oncology	Alessandra Raimondi, Pierangela Sepe et al.	45
19	Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence	BMC Cancer	Luigi Celio, Erminio Bonizzoni et al.	18
20	Predictors of mortality after admission to pediatric intensive care unit in oncohematologic patients without history of hematopoietic stem cell transplantation: A single‐center experience	Pediatric Blood & Cancer	Marta Pillon, Francesca Sperotto et al.	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact